Randy Lewarchik

@Henrik_on_HL Here's an answer for you henrik 😀. I think it's appropriate to compare hyperliquid verse a QQQ high gross tech stock. x.com/i/grok/share/a…

Since March 2026, we have observed that the price of $HYPE and Hyperliquid’s revenue are no longer positively correlated. Despite flat revenue, the price of $HYPE has been increasing. What do you think is the reason for this change?

@KyleSamani @toly @santiagoroel Yes, hyperliquid has one hell of a moat. The house of all finance!!!!

@santiagoroel There are moats

There are no moats Just persistence and speed

@Mylovanov Maybe this is incorrectly translated into English, but that's really sad if she barely speaks to her 7-year-old daughter. Her daughter needs her but I'm very proud of how resilient she is and how she fights for the freedom and security of her people

Her daughter is 7. They barely speak. “When she calls me ‘Mom’, I’m like — who?” She hides the truth: “Mom doesn’t kill people.” The girl asks: “Will you teach me to fly?” — “Of course.” 10/

A 25-year-old Ukrainian drone commander watches 4 Russian soldiers ride into her crosshairs — then erases them with a machine the size of a crow. “I’m fighting two wars. One against the Russians. And one inside myself,” — FT. 1/

@reisnertobias Hip 4 live baby!! It is a beautiful day 🌞

gm and have a blessed day 😊

@HYPEconomist That's one small step for man, one giant leap for mankind"

HIP-4 IS LIVE

@x256xx The house of all finance. Yet again.....That's one small step for man, one giant leap for mankind"

HIP-4 just went live on mainnet Hyperliquid

$IBRX A woman walks into an oncology clinic with stage IV non-small cell lung cancer. She's given six to eight weeks to live. Her doctor prescribes Keytruda. Nobody mentions a number called LIPI. But the number on her chart, if anyone had calculated it, would have predicted exactly how this ends. 4.5 months. That was the median survival of patients with the worst lymphocyte profile on the drug she was about to receive. The number was published in October 2019 in JAMA Oncology. The fourth author was Richard Pazdur, the man running FDA's Oncology Center of Excellence. THE PAPER Pazdur and four colleagues had analyzed 3,987 patients across eleven international randomized trials submitted to FDA between January 1, 2013 and December 31, 2017. Their score combined two lab values: lactate dehydrogenase level (LDH) and derived neutrophil-to-lymphocyte ratio (dNLR). The denominator that mattered was lymphocyte count. Their conclusion: LDH and dNLR are important prognostic biomarkers irrespective of treatment modality for patients with metastatic NSCLC. Without lymphocytes, the patient dies. THE NUMBERS Read the Pazdur paper's own data, broken out by LIPI score: LIPI score 0 (good lymphocyte profile) on a checkpoint inhibitor: median overall survival 15.6 months. 95% CI 13.5-17.6. Hazard ratio 0.34. n=620. LIPI score 1 (intermediate): 8.9 months. 95% CI 7.9-9.7. Hazard ratio 0.59. n=583. LIPI score 2 (poor): 4.5 months. 95% CI 3.0-6.2. Hazard ratio 1.0 reference. n=165. The same LIPI score 2 patients on cytotoxic chemotherapy: 5.3 months median OS. 95% CI 4.3-6.3. n=184. Read those last two lines again. The LIPI 2 patient on a checkpoint inhibitor had an 0.8-month shorter median survival than the LIPI 2 patient on cytotoxic chemotherapy. Twenty-four days. Global log-rank P value across both arms: less than 0.001. The most expensive cancer drug in the world, performed worse than older cytotoxic regimens for the population whose lymphocytes had been depleted. Pazdur and his colleagues published that conclusion. The author affiliation listed on the paper: FDA's Oncology Center of Excellence and Center for Drug Evaluation and Research, Silver Spring, Maryland. Merck reported approximately $30 billion a year in checkpoint inhibitor revenue. Over the last five years that is roughly $150 billion. For LIPI 2 patients, the drug those billions paid for did less than chemo. THE ASK Pazdur closed his paper with one specific request: "As further prospective clinical trial information is collected, the role of the LIPI score can be better defined." He asked for a trial. Six years passed. THE GAP The paper didn't go away. It sat in JAMA Oncology, fully indexed, fully cited, fully available. The man who wrote it kept running FDA's cancer office until November 2025, when he was promoted to lead all FDA drug approvals as director of CDER. Six weeks later he retired, citing concerns about institutional dysfunction. He had served 26 years. Then in January 2026, someone read the paper and acted on it. Not the agency he ran. Saudi Arabia. WHAT SAUDI DID The Saudi Food and Drug Authority approved ANKTIVA for second-line metastatic NSCLC after reviewing 1.7 million pages of clinical data. The label, verbatim: "approved under accelerated approval based on the increase of ALC associated with overall survival in single arm study. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory clinical trials." ALC is absolute lymphocyte count. The same biomarker Pazdur had identified as critical six years earlier. The Saudis didn't write a new theory. They acted on the theory the FDA's own senior cancer official had already published. The supporting trial: 150+ patients with second-line metastatic NSCLC who had failed prior checkpoint inhibitors. Median overall survival on ANKTIVA combined with a checkpoint inhibitor: roughly 21 months. Median OS on docetaxel monotherapy in matched historical comparisons: roughly 7 months. Triple. The patients eligible for the Saudi label are second-line lung cancer patients who relapsed after standard of care. Translation: patients whose Keytruda or Opdivo stopped working. The exact population in Pazdur's 2019 paper. THE PATIENT In April, the woman PSS treated three years ago - the one given six to eight weeks - was still alive. Her tumors were gone from her right lung and shrinking in her left. PSS played her testimonial on Sean Spicer's show on April 13, 2026. Three and a half years later, she was answering questions on television. APRIL 27, 2026 Two weeks later, the ClinicalTrials.gov registration for ResQ201A-NSCLC, NCT06745908, was updated. The trial expanded from two arms to four. Two cohorts. Cohort A experimental arm: ANKTIVA 1.2 mg subcutaneous + tislelizumab 200 mg IV + docetaxel 75 mg/m² IV. Cohort A control: docetaxel monotherapy. Cohort B (new on April 27) experimental arm: ANKTIVA 1.2 mg subcutaneous + the patient's previously failed checkpoint inhibitor + docetaxel 75 mg/m² IV. Cohort B control: docetaxel monotherapy. Total enrollment: 507 patients. Phase 3. Two-to-one randomization within each cohort. Primary endpoint: overall survival at approximately twelve months. Stratification factors per registry: geographical region, NSCLC histology (squamous vs nonsquamous), actionable genomic alteration status. Recruiting status: active. The population: patients who failed prior CPI. The biomarker: lymphocyte count. The trial design: prospective, randomized, multinational. The trial Pazdur asked for in 2019 was now registered. Later that same afternoon, Patrick Soon-Shiong posted Pazdur's paper on X. He said he'd just discovered it that day. He quoted Pazdur's own conclusion. He named the Saudi label. He closed with two words. Stay tuned. THE TIMELINE July 12, 2007: NCI, NIH, FDA, AACR, and ASH convened a landmark workshop. 124 candidate immunotherapy agents were submitted, winnowed to 30 for presentation, ranked into a top 20. They ranked IL-15 number one. Manuscript finalized October 4, 2007. October 2019: Pazdur and four colleagues published the LIPI paper. Lymphocyte count predicts survival. They asked for a prospective trial. April 2024: ANKTIVA, an IL-15 superagonist, was approved in the United States for one indication. Bladder cancer. November 2025: Pazdur named director of CDER, the broader FDA office overseeing all drug approvals. December 2025: Pazdur retired, citing concerns about institutional dysfunction. 26 years of service. January 2026: Saudi Arabia approved ANKTIVA for second-line NSCLC, citing ALC and overall survival explicitly. April 21, 2026: ANKTIVA commercially available in Saudi Arabia. First patients identified. April 27, 2026: The trial Pazdur asked for in 2019 - ResQ201A Cohort B - registered on ClinicalTrials.gov. Later that same afternoon, PSS surfaced the paper. Today is May 1, 2026. The trial is enrolling. The Saudi launch is live. The United States has not approved ANKTIVA for non-small cell lung cancer. STAY TUNED Pazdur didn't have to be convinced of the science. He wrote it. The country whose agency published the paper is not the country that acted on it. The trial Pazdur asked for is enrolling now. He retired five months before he could see it. Stay tuned was not a hint. It was a calendar.

@HYPEconomist @WatcherGuru @grok x.com/i/grok/share/5…

@WatcherGuru @grok where on that list does hyperliquid rank?

JUST IN: Total spot crypto exchange volume surpasses $3.85 trillion so far in 2026. 1. Binance: $1.22 trillion 2. ByBit: $255 billion 3. Coinbase: $230 billion 4. Gateio: $227 billion 5. Crypto․com: $220 billion

@willywoo @dotkrueger I wouldnt dive in with odds like that. If the straight opens and a deal is struck where sanctions are lifted and oil flows.... btc will almost definitely surpass all time highs. Is that possibility 30% or less????

@dotkrueger From the data coming in, I give Loukas a 70% chance of being correct. Obviously you can change this Fred, you just need to start buying 1B USD a day, sustained, that should swing the odds to 70% this is a bottom.

Loukas is a non believer. How he sees the next 3 months going in a very specific pattern is insane to me.

@Henrik_on_HL Iran canceled peas talks with the US for Monday. And the US just attacked an Iranian ship. Both happened at before hype went down

Is $HYPE getting hacked or why is it dumping so hard

People-pleasing is a local problem. Extending human lifespan is a civilization-level responsibility. When you’re reshaping how humans interact with time, matter, energy, and inevitably consciousness the cost of trying to satisfy everyone isn’t just distraction—it’s dilution of impact. The stakes are too high for that.

If you’re a people pleaser, outgrowing it will be the biggest upgrade you will make to your life, family and career Trust me on this 🚀

@windupbusiness_ @Cryptodad4442 Roy first off I want to say I absolutely love slow horses...... Is this true are you closing the business Dr. Howell @crossbordercap

@Cryptodad4442 @RandyLewarchik I said Crossborder Capital had closed. Which is correct. What you are saying is noise.

LIQUIDITY: You don't want to make a career being on the other side of the great @crossbordercap's views on the liquidity cycle. That said, our Global Liquidity Model agrees with our friend @RaoulGMI in the debate below.

David, grok answered the question. But I want to be clear that if you go down this path I will preferentially own purr over a US based hype etf that will be trading soon. I was truthfully intending to sell my purr and convert it to the etf so as to eliminate counterparty risk. But if there was a method such as the proposed to create additional positive cash flow purr would be superior even if it converted the stream into additional hype per share. I guarantee if you made an announcement about a partnership to this end the stock would soar on the news and further differentiate itself from the other DAT "Ponzi" schemes. There would definitely be renewed light shown on hip 3-4 and purr as you make the rounds of interviews on bloomberg, cnbc and large bandwidth financial pods😀 x.com/i/grok/share/c…

David I am an enthusiastic purr investor I have hype exposure through CEX crypto accounts and hype:ch (ETP out of Switzerland). To be honest my largest exposure is through purr. I would grow that investment handsomely if this quote from Artemis is or will become true ......."2. DAT as a builder partnership. At current prices, 500k HYPE is roughly $23M. Most builder teams cannot self-fund that stake. A large holder like PURR (18.8M HYPE) is a natural counterparty: financing or partnering on HIP-3/HIP-4 deployments in exchange for a share of the market's fees. This creates a revenue stream and ecosystem influence that individual HYPE holders cannot replicate at scale."

Well - this was nice to read ... @HypeStrat $PURR @HyperliquidX

@CryptoHayes @HyperliquidX Hyperliquid price scenarios if it grows to Ethereum's market cap and beyond...... x.com/i/grok/share/8…

HIP4 enables binary options on @HyperliquidX I expect an explosion of volume. $HYPE = $150 is just the beginning.

@DariusDale42 @windupbusiness_ @crossbordercap @RaoulGMI grok does not agree that cross boarder has closed LOL

@windupbusiness_ @crossbordercap @RaoulGMI They did? I wasn’t aware. Seems odd. He has a big following.

Thanks @domcooke for spending months on researching and writing this piece. Einstein once said, "If you can't explain it simply, you don't understand it well enough." By that measure, Dom has blown me away with how deeply he came to understand Hyperliquid and what we're all building together. When someone asks what "housing all of finance" means, I'm proud to point them to this piece. I hope readers appreciate just how much Dom and his team put into their work. It reflects the thoughtful craft that is in Hyperliquid's DNA. Special thanks to @patrick_oshag for taking a bet on Hyperliquid's story.

@amitisinvesting Yes, but I actually don't think any of the llms will actually become profitable. I think just like palantir's Karp says it'll be commoditized Open sourced

you know, at this point in the SaaS selloff… all of these software companies should just buy Anthropic in the private markets over their own stock I genuinely think Salesforce buying Anthropic at some crazy valuation to put on their balance sheet would be better than them buying back shares to help with sentiment 💀

Great write up! I love how conservative your base case is. Outside of bitcoin the only truly useful efficacious fit for blockchain has been hyperliquid. "$85 by 2028". I think it flips xrp Solana maybe even Ethereum market cap which instead of a 2x I'm gunning for 5 to 27x if it reaches those market caps.

@JC_ParetsX Ibrx, hyperliquid and purr, aaoi, lite, dram All added shares dram is the only new purchase but already held ewy

I bought a computer hardware stock this week. Biotechs and banks each of the past 2 weeks. How about you? What did you buy?